Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility
Genor obtained marketing approval for its first product in China, one more is expected this year. Commercial execution remains the key near-term catalyst for the stock.
Equity Bottom-Up
404 Views, 09 May 2022 00:57
SUMMARY
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network